Clinical Trials
6 trialsNCT04184921 2026-02-03
Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT03543683 2025-02-27
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT06018688 2023-09-21
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT03532698 2020-07-23
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Unknown
NCT01707823 2020-01-14
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Terminated
NCT01058902 2016-03-07
The Effect Of Aspirin On Survival in Lung Cancer
Liverpool Heart and Chest Hospital NHS Foundation Trust
Phase 3 Withdrawn